uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of uniQure (NASDAQ:QURE) in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $70.00 price target on the biotechnology company’s stock.

Other analysts have also recently issued reports about the stock. Chardan Capital increased their target price on shares of uniQure from $16.00 to $31.00 and gave the stock a “buy” rating in a report on Monday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Mizuho reaffirmed a “neutral” rating and set a $12.00 price objective (down from $33.00) on shares of uniQure in a research report on Tuesday, March 3rd. Wolfe Research assumed coverage on shares of uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. Finally, Leerink Partners reissued an “outperform” rating and issued a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $41.33.

uniQure Price Performance

Shares of NASDAQ QURE opened at $18.26 on Tuesday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -5.29 and a beta of 0.73. uniQure has a twelve month low of $7.76 and a twelve month high of $71.50. The business has a 50 day simple moving average of $21.79 and a 200-day simple moving average of $29.66.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. As a group, equities research analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Gut sold 25,613 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 81,399 shares of company stock valued at $1,527,645. Company insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Woodline Partners LP increased its stake in shares of uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after purchasing an additional 35,175 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of uniQure during the second quarter worth approximately $151,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of uniQure during the second quarter worth approximately $215,000. SG Americas Securities LLC bought a new position in uniQure in the 2nd quarter worth approximately $1,321,000. Finally, Main Management ETF Advisors LLC grew its holdings in uniQure by 1.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after buying an additional 912 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Regulatory shift lifted sentiment — reports that the FDA biologics chief (CBER) will depart in April spurred a big rally, as market participants interpreted the move as easing near‑term regulatory friction around AMT‑130. UniQure shares surge 26% on US FDA shakeup
• Positive Sentiment: Street support increased — multiple firms (H.C. Wainwright, Chardan, RBC, Wells Fargo) reiterated/raised ratings and price targets (examples: $70, $31, $35, $60), reinforcing upside narratives and helping buying interest. uniQure: Regulatory Shift and AMT‑130 Outlook Drive Reaffirmed Buy Rating
• Neutral Sentiment: Brokerage consensus remains mixed — some outlets list a consensus “Hold” even as select brokers upgrade, indicating divergent views on risk/reward and continuing uncertainty about clinical/regulatory outcomes. uniQure receives consensus recommendation of “Hold”
• Negative Sentiment: Widespread securities litigation notices — numerous plaintiff firms have filed or announced class actions tied to disclosures from the Sept. 24–Oct. 31, 2025 period, with an April 13, 2026 lead‑plaintiff deadline; this raises litigation risk, potential discovery burdens and headline volatility. Kessler Topaz Meltzer & Check filed a securities fraud class action
• Negative Sentiment: Allegations from FDA scrutiny and law‑firm claims — a shareholder firm highlights a reported public rebuke by federal health officials accusing uniQure of pushing “distorted” or “manipulated” data for AMT‑130; such allegations amplify regulatory/legal risk and could pressure sentiment if substantiated. Hagens Berman: FDA reportedly accuses uniQure of distorted data
• Negative Sentiment: Elevated short interest — short interest rose ~17.6% in February to ~12.6M shares (~21.2% of float) with a days‑to‑cover of ~3.3, indicating meaningful bearish positioning that can amplify downward moves or create volatile squeezes.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.